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2006 and 2007. The WHO-Adverse Reaction Terminology
record entries were re-coded in International Classiﬁcation of
Diseases (ICD-10-GM Version 2008) format and afterwards
assigned to the matching DRG (G-DRG 2008) including supple-
mentary and additional fees. RESULTS: Incidence of internal
hospitalization was estimated to approximately 3.25%. Mean
age of patients was 71.3 years (SD 14.5). Average inpatient
length of stay in the group was 9.3 days (SD 7.0) and is therefore
2.3 days higher than average length of stay in German internal
wards (7.0 days in the year 2006). Most frequent ADRs are
gastrointestinal bleeding (n = 205), hypoglycemia (n = 201), and
bradycardia (n = 61). Average treatment costs of a single ADR
were estimated to be approximately €2044 based on a state-wide
base-rate of €2800. CONCLUSIONS: Before the introduction of
the DRG system, direct medical costs of ADR-treatment in
Germany were €400 million in the year 2002 (Schneeweiss et al.,
Eur J Clin Pharmacol 2002;58:285–91. This equals—given an
ADR-incidence of 2.1%—case-related costs of €3,700 per
person. Our results provide an informative basis, that this former
person-related amount seems to be too high against the back-
ground of DRG introduction. Considering the apparently higher
incidence rate of 3.25%, the present total costs are approxi-
mately the same.
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OBJECTIVES: On the May 1, 2004 Hungary—together with
many European countries—joined the European Union which
resulted in several changes in the Hungarian legislation. In the
coverage policy of pharmaceuticals, the Directive 89/105/EEC of
the Council of the European Communities on Transparency was
implemented in Hungary, in order to provide regulation on deci-
sion on drug prices. The aim of our study is to calculate the
average delay of decision-making on pharmaceutical reimburse-
ment. METHODS: The data derive from the drug reimburse-
ment database of the National Health Insurance Fund
Administration (OEP) of Hungary covering the 3 year period of
2005–2007. We calculated the delay as the time between the
submission of application by the manufacturer and the ﬁrst day
of reimbursement of drug. Our analysis covered drugs submitted
within the frame of normal procedure, drugs submitted in the
simpliﬁed procedure were omitted. RESULTS: Between 2005–
2007, the total number of applications was 172, 161, 140; while
the average delay was 217, 255, 166 days respectively. Most of
the application represented new (innovative) drugs (70, 75, 65
pieces) or new indications of drugs already reimbursed in other
indication (27, 28, 27 pieces). Between 2005–2007 the average
delay for new (innovative) drugs was 258, 222, 166 days, while
for new indications it was 194, 319, 203 days respectively. CON-
CLUSIONS: The introduction of EU transparency directive
provided a strong regulatory framework for decision-making
process on drug reimbursement. In the normal procedure we
found signiﬁcant differences in time delay of decision according
to submission categories. However, in 2007 the average delay
signiﬁcantly decreased compared to previous years.
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OBJECTIVES: In 2006, pharmaceuticals were sold in Finland
approximately €2.4 billion (a 1.6% reduction from 2005).
However, pharmacy and hospital markets may have performed
in different ways. The objective is to develop descriptive
performance indicators for pharmaceutical market dynamics in
Finland. METHODS: Total numbers of marketers (M), active
substances (S), trade names (T) and packages (P) (1995–2007)
were extracted from the market database SLD Pharma (Finnish
Pharmaceutical Data Ltd.). We restricted data only to numbers
that were associated with a marketing authorisation and positive
annual wholesale ﬁgures. Total number and indicator (S/M, T/M,
P/M, T/S, P/T, P/S) analyses were segmented by markets (phar-
macy, hospital) and calendar year. We compared ﬁgures in 2007
to base year 1995. RESULTS: In 2007 pharmacy market, the
total number of marketers was 38% (26% in hospital market),
active substances 15% (18%), trade names 44% (28%), and
packages 26% (12%) higher than in 1995. Compared to 1995,
the pharmacy market S/M indicator in 2007 was 0.83 (0.93 in
hospital market), whereas T/M was 1.04 (1.02), P/M was 0.91
(0.89), T/S was 1.25 (1.09), P/T was 0.88 (0.87), and P/S was
1.10 (0.95). CONCLUSIONS: In Finland 1995–2007 numbers
of marketers, trade names (products) and sales packages in-
creased more in the pharmacy market. Pharmacy market indica-
tors (S/M -17%, T/S +25%, P/S +10%) suggest an increase in
competition, and may partly be explained by generic substitution
that was introduced in Finland on 1 April 2003.
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